মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

rebel distributors corp - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 400 mg in 40 ml - ciprofloxacin injection, usp is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. please see dosage and administration for specific recommendations. adult patients:   urinary tract infections caused by escherichia coli (including cases with secondary bacteremia), klebsiella pneumoniae subspecies pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter diversus , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . lower respiratory infections caused by escherichia coli , klebsiella pneumoniae subspecies pneumoniae , enterobacter cloacae , proteus mirabilis , pseudomonas aeruginosa , haemophilus

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

rebel distributors corp - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 10 mg in 1 ml - ciprofloxacin injection is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli (including cases with secondary bacteremia), klebsiella pneumoniae subspecies pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. lower respiratory infections caused by escherichia coli, klebsiella pneumoniae subspecies pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-suscepti

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

juniper healthcare pte ltd - palonosetron hydrochloride 0.28 mg/5ml eqv palonosetron - injection, solution - 50mcg/ml - palonosetron hydrochloride 0.28 mg/5ml eqv palonosetron 50mcg/ml

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

mgi pharma - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - injection - 0.25 mg in 5 ml - aloxi is indicated for: • moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses • highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses aloxi is indicated for: • prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. [see adverse reactions (6.2 )] teratogenic effects: category b teratology studies have been perfo

ইস্রায়েল - ইংরেজি - Ministry of Health

perrigo israel agencies ltd - digoxin - solution for injection - digoxin 0.5 mg / 2 ml - digoxin - digoxin - for management of chronic cardiac failure,and certain supraventricular arrhythmias.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

northstar rxllc - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - • irinotecan hydrochloride injection, is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. • irinotecan hydrochloride injection, is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinot

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

armas pharmaceuticals inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - • irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. in separate studies in rats, this dose produced an irinotecan cmax and auc of

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

sandoz inc - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 2 mg in 1 ml - ciprofloxacin injection, usp is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli (including cases with secondary bacteremia), klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter koseri (diversus), citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or vancomycin-susceptible enterococcus faecalis . lower respiratory infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae , or penicillin-susceptible st

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

cardinal health - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 2 mg in 1 ml - ciprofloxacin injection, usp in 5% dextrose is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration is needed [see dosage and administration (2.1, 2.2) ]. ciprofloxacin injection, usp in 5% dextrose is indicated in adult patients for treatment of urinary tract infections caused by escherichia coli , klebsiella pneumoniae, enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter koseri , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . ciprofloxacin injection, usp in 5% dextrose is indicated in adult patients for treatment of lower respiratory tract infections caused by escherichia coli , klebsiella pneumoniae, enterobacter cloacae , proteus mirabilis , pseudomonas aeruginosa , haemophilus influen

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron .25 mg in 2 ml - palonosetron hydrochloride (hcl) injection is indicated for: •     moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses •     highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses palonosetron hcl injection is contraindicated in patients known to have hypersensitivity to the drug or any of its components [see adverse reactions (6.2)] . r i sk summary there are no available data on palonosetron hcl use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron hcl to rats and rabbits during organogenesis at doses up to 1894 and 3789 times the recommended human intravenous dose, respectively [see data]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  in the u.s. general popula